A biopharmaceutical company focused on cancer
Invectys Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by two veterans from the Institut Pasteur, Pierre Langlade-Demoyen and Simon Wain-Hobson.
Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumor antigens: the HLA-G immune checkpoint expressed in over 50% of cancers and the nearly-universal tumor antigen telomerase that is critical to uncontrolled cell growth.
Invectys has created two complementary technological platforms to reach its goals:
- HLA-G-based therapies
- Telomerase-based vaccines, with IVS-1001 and IVS-2001
Winning the CPRIT Award in November 2020, Invectys has raised more than $60 million. It is backed by French and international private investors and has received financial grants from the French state.
Invectys’ approach has significant benefits compared to traditional oncology approaches:
- targets most cancers
- induces higher and more robust anti-tumor responses than those obtained with other products
- a very innovative approach with no marketed competing products
- addresses an unmet market
- is more cost effective than competing treatments.
Core Assets to be Funded
- Lead platform: therapies based on the novel Immune Checkpoint HLA-G
- IVS-1001: telomerase peptide vaccine, designed to activate CD4+ helper T cells
- Encouraging pre-clinical results: confirmed specificity of the immune response, proliferation of Th1 cells, increased tumor-specific CD8+ response, no serious vaccine-related toxicity
- Phase I/II in Non-Small Cell Lung Cancer (NSCLC) at the Besançon University
- Early clinical results: increased CD4+ response against telomerase in 60% of patients
- IVS-2001: State-of-the-art DNA Vaccine developed trough proprietary human telomerase vaccine platform
- Phase IIa in planning in multiple indications, standalone or in combinations
- Efficacy: 65% one-year survival rate, 58% patients experiencing disease stabilisation, 6 patients still alive as of June 2020
Invectys highlights & achievements
- An advanced pipeline exploiting several technologies:
- Innovative HLA-G platform with both MAb and CAR-T potential
- Telomerase-based therapeutic vaccines
- Potential in multiple cancers for both cancers:
- Multiple avenues for combination studies
- Unique prophylactic potential in early-stage and rapid-progression malignancies
- Dominant know-how in Telomerase approaches:
- Institut Pasteur legacy
- Ongoing academic studies at University of Besançon
- Multiple opportunities for partnership with pharma companies
- Strong IP (14 patents filed)
- Historic shareholder support
- Talented and seasoned team, supported by strong Strategic and Scientific Advisory Boards